• Differential Shh, Fgf10, and Fgfr2 Expression Shapes Penile

  2026-04-30

  This study dissects species-specific penile development by comparing Shh, Fgf10, and Fgfr2 expression in guinea pigs and mice. The findings clarify mechanisms underlying urethral groove and prepuce formation, with implications for understanding human genital morphogenesis.

• Antimycin A4 as a Precision Metabolic Blocker: Structural In

  2026-04-30

  Explore the multifaceted role of Antimycin A4 as an ATP-citrate lyase inhibitor and mitochondrial research tool. This article uniquely dissects structure–activity relationships and protocol design considerations, offering actionable guidance for advanced energy metabolism studies.

• β-Adrenergic Blockade Impacts Hematopoietic Regeneration Pos

  2026-04-29

  This study demonstrates that nonselective β-adrenergic receptor blockers impair hematopoietic regeneration after hematopoietic cell transplantation (HCT), while β1-selective inhibition does not. The findings have significant implications for the selection of β-blocker regimens in clinical and experimental transplantation settings.

• Tin Mesoporphyrin IX: Precision Inhibition in Heme Oxygenase

  2026-04-29

  Explore how Tin Mesoporphyrin IX (chloride) delivers unparalleled precision in heme oxygenase activity assays, with a focus on its advanced kinetic profile and implications for metabolic disease research. This article reveals unique protocol strategies and bridges fundamental enzymology with translational insights.

• Vidarabine Monohydrate: Expanding Antiviral Assay Frontiers

  2026-04-28

  Explore Vidarabine monohydrate as a unique antiviral research compound. This article reveals its assay-defining solubility and mechanistic specificity, offering guidance not found in existing resources.

• BGJ398 (NVP-BGJ398): Selective FGFR Inhibitor for Oncology R

  2026-04-28

  BGJ398 (NVP-BGJ398) is a potent and selective FGFR1/2/3 inhibitor used to study FGFR-driven malignancies and apoptosis in cancer cells. Its nanomolar potency and selectivity profile enable precise modulation of FGFR signaling in oncology research applications.

• Modeling HSV-1 Latency in Human iPSC-Derived Sensory Neurons

  2026-04-27

  This study establishes a scalable protocol to differentiate human inducible pluripotent stem cells (hiPSCs) into sensory neurons capable of supporting HSV-1 latent infection and reactivation. The work provides a human-specific platform for mechanistic studies of HSV-1 latency and opens avenues for evaluating therapeutic strategies that were previously limited to animal models.

• IL-18-Based Tools Reveal Overlapping Caspase-1 and Caspase-8

  2026-04-27

  This study introduces a novel IL-18 tetrapeptide-based inhibitor, uncovering unexpected substrate and inhibitor specificities shared between inflammatory and apoptotic initiator caspases. The findings reveal that VX-765, while widely used for selective caspase-1 inhibition, also targets caspase-8, informing future assay design and interpretation.

• Z-IETD-FMK: Precision Caspase-8 Inhibition in Cell Death Ass

  2026-04-26

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) enables precise dissection of caspase-8-dependent pathways in apoptosis and immune activation studies. This guide translates recent insights—including the mechanistic bridge to avian pyroptosis—into actionable workflows and troubleshooting strategies for advanced cell death research.

• Targeting Extracellular Vesicle Release in Triple-Negative B

  2026-04-25

  McNamee et al. present a comprehensive evaluation of small molecule inhibitors, including the calpain inhibitor Calpeptin, for suppressing extracellular vesicle (EV) release from triple-negative breast cancer (TNBC) cells. Their findings demonstrate that broad inhibition of EV release can significantly reduce the transmission of aggressive cancer traits, highlighting the potential of EV-targeted approaches in TNBC research.

• Topotecan’s Mechanistic Advances and Implications for Cancer

  2026-04-24

  This review highlights the pharmacological innovation of topotecan, a topoisomerase I inhibitor with a unique DNA-damaging mechanism distinct from alkylating chemotherapeutic agents. The article synthesizes findings on topotecan’s clinical efficacy, toxicity profile, and its evolving role in combination regimens for challenging cancers such as ovarian and small cell lung cancer.

• mCherry mRNA: Advancing Reporter Assays with Enhanced Stabil

  2026-04-24

  Unlock high-fidelity, immune-evasive fluorescent reporting with EZ Cap™ mCherry mRNA (5mCTP, ψUTP). APExBIO’s next-generation mRNA tool empowers robust protein expression, improved signal stability, and seamless integration into advanced cell biology and high-throughput redox workflows.

• SAFB and Satellite RNAs Stabilize Heterochromatin via Phase

  2026-04-23

  Huo et al. (2020) reveal that the nuclear matrix protein SAFB interacts with major satellite RNAs to maintain the higher-order structure of pericentromeric heterochromatin, partly through phase separation. This work advances the molecular understanding of genome organization and provides new frameworks for transcriptional regulation research.

• SB743921: Precision KSP Inhibition and the Future of Cancer

  2026-04-23

  Explore the scientific depth of SB743921, a leading kinesin spindle protein inhibitor, and discover how nuanced in vitro assay insights are transforming cancer research and preclinical drug evaluation.

• Imeglimin Enhances Mitochondrial Function in Carpal Tunnel S

  2026-04-22

  This study provides the first direct evidence that Imeglimin improves mitochondrial function in subsynovial connective tissue cells from idiopathic carpal tunnel syndrome (CTS) patients. By integrating quantitative mitochondrial assessments—including membrane potential, volume, and permeability transition pore status—the work suggests a targeted strategy to address mitochondrial dysfunction in CTS.

11107 records 1/741 page Next 12345 下5页 Last page